Skip to main content
SpringerLink
Log in

Stroke Prevention With Antiplatelet Therapy

  • Chapter
Handbook of Stroke Prevention in Clinical Practice

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

Community-based stroke studies have shown that approx 80% of all strokes are ischemic (1,2). The majority of patients survive their first ischemic stroke, with 95% alive at 7 days poststroke and 90% alive at 1 month (3). These patients subsequently have an increased risk of stroke recurrence of approx 5% per annum and an increased risk of serious coronary events of about 3% per annum over the following 5 years (4,5).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Warlow CP, Dennis MS, van Gijn J, et al. What pathological type of stroke is it? In: Warlow CP, Dennis MS, van Gijn J, et al., eds. Stroke. A Practical Guide to Management. Oxford, UK: Blackwell Science, 1996:146–189.

    Google Scholar 

  2. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994;25:333–337.

    Article  PubMed  CAS  Google Scholar 

  3. Warlow CP, Dennis MS, van Gijn J, et al. A practical approach to the management of stroke patients. In: Warlow CP, Dennis MS, van Gijn J, et al., eds. Stroke. A Practical Guide to Management. Oxford, UK: Blackwell Science, 1996:360–384.

    Google Scholar 

  4. Warlow CP. Epidemiology of stroke. Lancet 1998;352(Suppl 3):1–4.

    Article  Google Scholar 

  5. McCabe DJH, Brown MM. Early prevention of stroke recurrence. In: Bogousslavsky J, ed. Drug Therapy for Stroke Prevention. London: Taylor and Francis, 2001:168–188.

    Chapter  Google Scholar 

  6. Grau AJ, Ruf A, Vogt A, et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998;80:298–301.

    PubMed  CAS  Google Scholar 

  7. Meiklejohn DJ, Vickers MA, Morrison ER, et al. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001;112:621–631.

    Article  PubMed  CAS  Google Scholar 

  8. Yamazaki M, Uchiyama S, Iwata M. Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 2001;104:197–205.

    Article  PubMed  CAS  Google Scholar 

  9. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood 1994;83:885–898.

    PubMed  CAS  Google Scholar 

  10. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.

    Article  PubMed  CAS  Google Scholar 

  11. Fitz Gerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433–442.

    Article  Google Scholar 

  12. Harker LA. Therapeutic inhibition of platelet function in stroke. Cerebrovasc Dis 1998;8(Suppl5):8–18.

    Article  PubMed  Google Scholar 

  13. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569–1581.

    Article  Google Scholar 

  14. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997;349:1641–1649.

    Article  Google Scholar 

  15. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995;346:1509–1514.

    Google Scholar 

  16. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI2: a factorial randomized trial of alteplase vs streptokinase and heparin vs no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65–71.

    Google Scholar 

  17. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.

    Article  Google Scholar 

  18. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044–1054.

    Article  PubMed  CAS  Google Scholar 

  19. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;338:1345–1349.

    Article  Google Scholar 

  20. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261–1266.

    Article  Google Scholar 

  21. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.

    Article  PubMed  CAS  Google Scholar 

  22. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol Neurosurg Psychiatry 1996;60:197–199.

    Article  PubMed  CAS  Google Scholar 

  23. Johnson ES, Lanes SF., Wentworth CE III, Satterfield MH, Abebe BL, Dicker LW. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999;159:1248–1253.

    Article  PubMed  CAS  Google Scholar 

  24. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

    Article  Google Scholar 

  25. Warlow C. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke 2002;33:2137–2138.

    Article  PubMed  Google Scholar 

  26. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308: 81–106.

    Article  Google Scholar 

  27. European Carotid Surgery Trialists’ Collaborative Group. Randomized trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379–1387.

    Article  Google Scholar 

  28. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–453.

    Article  Google Scholar 

  29. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996;88:1525–1541.

    PubMed  CAS  Google Scholar 

  30. Uchiyama S, Yamazaki M, Maruyama S, et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994;25:1547–1551.

    Article  PubMed  CAS  Google Scholar 

  31. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999;353: 2179–2184.

    Article  PubMed  CAS  Google Scholar 

  32. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255–1262.

    Google Scholar 

  33. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240–1249.

    Article  PubMed  CAS  Google Scholar 

  34. Coté R, Battista RN, Abrahamowicz M, Langlois Y, Bourque F, Mackey A. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Ann Intern Med 1995;123:649–655.

    PubMed  Google Scholar 

  35. Wolf PA, Clagett P, Easton JD, et al. Preventing stroke in patients with prior stroke and transient ischemic attack. Stroke 1999;30:1991–1994.

    Article  PubMed  CAS  Google Scholar 

  36. FitzGerald G.A. Dipyridamole. N Engl J Med 1987;316:1247–1257.

    Article  Google Scholar 

  37. Eisert WG. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 2001;57:S20-S23.

    Article  PubMed  CAS  Google Scholar 

  38. Diener HC. Antiplatelet drugs in secondary prevention of stroke. Int J Clin Pract 1998;52:91–97.

    PubMed  CAS  Google Scholar 

  39. ESPS Group. European Stroke Prevention Study. Stroke 1990;21:1122–1130.

    Article  Google Scholar 

  40. Wilterdink JL, Easton JD. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999;56:1087–1092.

    Article  PubMed  CAS  Google Scholar 

  41. ESPRIT investigators. Anticoagulants vs aspirin and the combination of aspirin and dipyridamole vs aspirin only in patients with transient ischemic attacks or nondisabling ischemic stroke: ESPRIT (European and Australian Stroke Prevention in Reversible Ischemia Trial). Major ongoing stroke trials [abstract]. Stroke 1999;30: 1301.

    Article  Google Scholar 

  42. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998;273:2024–2029.

    Article  PubMed  CAS  Google Scholar 

  43. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998;273:2030–2034.

    Article  PubMed  CAS  Google Scholar 

  44. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202–207.

    Article  PubMed  CAS  Google Scholar 

  45. Schrgr K. The basic pharmacology of ticlopidine and clopidogel. Platelets 1993;4: 252–261.

    Article  Google Scholar 

  46. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667–1672.

    Google Scholar 

  47. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86:222–232.

    PubMed  CAS  Google Scholar 

  48. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215–1220.

    Article  PubMed  CAS  Google Scholar 

  49. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501–507.

    Article  PubMed  CAS  Google Scholar 

  50. Bennett CL, Connors JM,Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773–1777.

    Article  PubMed  CAS  Google Scholar 

  51. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996;348:1329–1339.

    Article  Google Scholar 

  52. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891–896.

    PubMed  CAS  Google Scholar 

  53. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25(Suppl 2):15–19.

    PubMed  CAS  Google Scholar 

  54. Bennett CL, Connors JM, Moake JL. Clopidogrel and thrombotic thrombocytopenic purpura [letter (response)]. N Engl J Med 2000;343:1193–1194.

    Google Scholar 

  55. Cheung RT. Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med 2000;343:1192–1194.

    PubMed  CAS  Google Scholar 

  56. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. (1996) Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 88,907–914.

    PubMed  CAS  Google Scholar 

  57. Moran N, Fitz Gerald GA. Mechanisms of action of antiplatelet drugs. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: J. B. Lippincott, 1994:1623–1637.

    Google Scholar 

  58. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353: 227–231.

    Article  PubMed  CAS  Google Scholar 

  59. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000;31:601–609.

    Article  Google Scholar 

  60. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001;86:427–443.

    PubMed  CAS  Google Scholar 

  61. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebocontrolled international trial of oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399–406.

    Article  PubMed  CAS  Google Scholar 

  62. Sandercock P. Antiplatelet therapy with aspirin in acute ischemic stroke. Thromb Haemost 1997;78:180–182.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Dominick J. H. McCabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Philip Kistler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Boston, MA, USA

    Karen L. Furie MD, MPH  & Peter J. Kelly MD, MS, MRCPI  & 

  2. Harvard Medical School, Boston, MA, USA

    Karen L. Furie MD, MPH

  3. Mater Misericordiae University Hospital, Dublin, Ireland

    Peter J. Kelly MD, MS, MRCPI

  4. University College, Dublin, Ireland

    Peter J. Kelly MD, MS, MRCPI

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

McCabe, D.J.H., Kelly, P.J., Kistler, J.P. (2004). Stroke Prevention With Antiplatelet Therapy. In: Furie, K.L., Kelly, P.J. (eds) Handbook of Stroke Prevention in Clinical Practice. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-769-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-769-7_8

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9856-1

  • Online ISBN: 978-1-59259-769-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation